FJI.F FUJIFILM Earnings Preview May 8, 2026

FUJIFILM Holdings Corporation (FJI.F) will report earnings on May 8, 2026, with analysts expecting $0.3307 earnings per share and $4.77 billion in revenue. The Japanese conglomerate operates across healthcare, materials, business innovation, and imaging segments. With a market cap of $19.50 billion and trading at €15.875, the stock has gained 1.70% recently but remains down 13.41% over the past year. Investors will focus on whether FUJIFILM can sustain recent momentum and deliver on analyst expectations across its diversified business portfolio.

Earnings Estimates and What They Mean

Analysts project FUJIFILM will earn $0.3307 per share this quarter, representing a significant portion of the company’s trailing twelve-month EPS of $1.20. The $4.77 billion revenue estimate reflects steady demand across the company’s four main divisions. These figures suggest modest quarterly performance relative to annual results. The company’s 13.48 PE ratio indicates investors value FUJIFILM at a reasonable multiple compared to historical averages. Strong cash generation remains critical, with operating cash flow per share at $332.75 trailing twelve months.

Revenue Growth Trajectory

FUJIFILM’s trailing twelve-month revenue per share stands at $2,745.85, showing the company’s substantial revenue base. Recent financial growth data shows 7.93% annual revenue growth, indicating steady expansion. The company’s gross profit margin of 40.54% demonstrates solid pricing power and cost management. With 722,540 full-time employees globally, FUJIFILM maintains significant operational scale. Investors should monitor whether quarterly revenue meets the $4.77 billion consensus or shows acceleration in key segments.

Earnings Quality and Profitability

FUJIFILM’s net profit margin of 8.27% reflects moderate profitability across its diversified operations. The company generated $226.99 net income per share trailing twelve months, showing consistent earnings power. Operating income grew 19.31% year-over-year, suggesting improving operational efficiency. The effective tax rate of 25.59% remains stable and predictable. Investors should watch for margin expansion or contraction signals during the earnings call.

Key Metrics and Financial Health

FUJIFILM maintains a solid balance sheet with a current ratio of 1.43, indicating strong short-term liquidity. The company’s debt-to-equity ratio of 0.31 shows conservative leverage and financial stability. With $156.15 cash per share, FUJIFILM has substantial resources for operations and investments. The company’s return on equity of 7.84% reflects moderate profitability relative to shareholder capital. These metrics suggest FUJIFILM can weather economic uncertainty while funding growth initiatives.

Dividend and Shareholder Returns

FUJIFILM pays $69.28 per share in annual dividends, delivering a 2.33% dividend yield. The payout ratio of 30.84% leaves room for dividend growth or reinvestment. Dividend per share grew 21.62% year-over-year, rewarding long-term shareholders. The company’s strong cash generation supports sustainable dividend payments. Investors seeking income should note FUJIFILM’s consistent dividend track record and growth trajectory.

Capital Allocation and Investment

The company invests heavily in research and development at 4.88% of revenue, supporting innovation across segments. Capital expenditures represent 16.07% of revenue, indicating ongoing modernization efforts. Free cash flow per share turned negative at -$108.37 trailing twelve months, primarily due to high capital spending. This investment posture suggests management prioritizes long-term growth over short-term cash returns. Investors should assess whether these investments drive future earnings acceleration.

Segment Performance and Business Drivers

FUJIFILM’s healthcare segment provides medical devices, biomedical contract manufacturing, pharmaceuticals, and regenerative medicine solutions. This division addresses prevention, diagnosis, and treatment across global markets. The materials segment offers inkjet printing technology, storage media, and industrial materials for semiconductors and displays. These segments benefit from secular trends in healthcare and digital transformation. The business innovation division provides office devices, printers, and document services. The imaging segment serves photography, cinema, and industrial inspection markets.

Healthcare Segment Momentum

Healthcare represents FUJIFILM’s highest-growth division, driven by aging populations and increased medical spending. Biomedical contract manufacturing services show strong demand from pharmaceutical companies. Regenerative medicine and cosmetics products address premium market segments. The company’s medical device portfolio expands into diagnostic imaging and treatment solutions. Investors should monitor healthcare revenue contribution and margin trends during earnings.

Materials and Imaging Resilience

The materials segment faces cyclical demand from semiconductor and display manufacturers. Inkjet printing technology adoption continues in commercial printing applications. The imaging segment maintains stable revenue from film photography enthusiasts and cinema markets. Industrial lens and surveillance camera sales provide steady recurring revenue. These segments offer diversification but face structural headwinds from digital disruption.

What to Watch and Meyka AI Assessment

Investors should focus on whether FUJIFILM beats or misses the $0.3307 EPS estimate and $4.77 billion revenue target. Management guidance for the full fiscal year will signal confidence in business momentum. Segment-by-segment performance breakdown reveals which divisions drive growth. Operating margin trends indicate pricing power and cost discipline. Cash flow generation and capital spending plans matter for dividend sustainability and shareholder returns.

Meyka AI Grade and Outlook

Meyka AI rates FJI.F with a grade of B, reflecting balanced fundamentals and moderate growth prospects. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. The rating suggests FUJIFILM offers reasonable value at current prices but lacks exceptional upside catalysts. The company’s A- fundamental rating from our analysis indicates solid financial health and operational execution. These grades are not guaranteed and we are not financial advisors.

Technical and Valuation Signals

The stock’s RSI of 49.48 indicates neutral momentum with no overbought or oversold conditions. The PE ratio of 13.48 trades below the company’s historical average, suggesting potential value. Year-to-date performance of -11.85% reflects broader market weakness rather than company-specific issues. The price-to-book ratio of 0.96 indicates the stock trades below tangible asset value. Technical indicators suggest patience before major directional moves.

Final Thoughts

FUJIFILM Holdings faces a critical earnings test on May 8, 2026, with expected EPS of $0.3307 and revenue of $4.77 billion. Its diversified portfolio across healthcare, materials, business innovation, and imaging provides stability. Strong balance sheet metrics and consistent dividend growth support a constructive outlook, though free cash flow challenges and cyclical exposure require monitoring. The B-grade reflects solid fundamentals without exceptional growth catalysts. Investors should track segment performance, management guidance, and cash flow generation to determine if FUJIFILM can sustain momentum and justify current valuation.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Earnings estimates are analyst projections and not guarantees of actual results. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.